← 返回前沿论文

鉴定 CD320、SLC44A1 和 TNFRSF13B 作为多发性骨髓瘤 CAR-T 细胞治疗的潜在新靶点

英文原题:Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma.

查看英文原题

Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma.

PubMed 2026/01/13(内容时间) Front Med (Lausanne) Q1 · IF 3.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

CD320、SLC44A1 和 TNFRSF13B 是多发性骨髓瘤中 CAR-T 细胞疗法有前景且具临床相关性的靶点。

中文摘要

我们分析了11个公开单细胞RNA测序数据集,数据来自意义未明单克隆丙种球蛋白血症(MGUS)、冒烟型MM(SMM)、MM、复发/难治性MM(RRMM)患者及健康供者。通过生物信息学筛选鉴定浆细胞特异性表面蛋白,并在约2000例患者的外部整体转录组数据库中验证,且通过流式细胞术检测MM细胞系和原代骨髓样本。

我们鉴定出15种浆细胞相关表面蛋白,包括BCMA、CD138、CD38和SLAMF7。随后优先考察5种分子:TNFRSF13B(TACI)、CD59、FCGR2B(CD32B)、SLC44A1(CD92)和CD320。CD320和SLC44A1随疾病分期上调,并与生存较差相关;TNFRSF13B、CD59和FCGR2B则在晚期疾病中富集,并与较好结局相关。细胞遗传学聚类显示这些分子与特定遗传背景相关,提示其表达模式可能受亚型影响。流式细胞术证实CD59、SLC44A1、TNFRSF13B和CD320的表面表达。 讨论:CD320、SLC44A1和TNFRSF13B是MM CAR-T 疗法具有前景且临床相关的靶点。其分期特异性表达和预后意义支持将其用于增强现有免疫治疗策略。

展开英文摘要原文

We analyzed 11 publicly available single-cell RNA sequencing datasets from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), MM, relapsed/refractory MM (RRMM) and healthy donors. Plasma cell-specific surface proteins were identified via bioinformatic filtering and validated on external bulk transcriptomic database of ~2,000 patients and by flow cytometry on MM cell lines and primary bone marrow samples.

We identified 15 plasma cell-associated surface proteins, including BCMA, CD138, CD38, and SLAMF7. Five molecules-TNFRSF13B (TACI), CD59, FCGR2B (CD32B), SLC44A1 (CD92), and CD320-were prioritized for further study. CD320 and SLC44A1 were upregulated with disease stage and associated with poor survival, while TNFRSF13B, CD59, and FCGR2B were enriched in advanced disease and linked to better outcomes. Cytogenetic clustering linked these molecules to specific genetic backgrounds, suggesting subtyperelated expression patterns. Flow cytometry confirmed the surface expression of CD59, SLC44A1, TNFRSF13B and CD320. DISCUSSION: CD320, SLC44A1, and TNFRSF13B are promising, clinically relevant targets for CAR T-cell therapy in MM. Their stage-specific expression and prognostic significance support their potential to enhance existing immunotherapeutic strategies.

论文信息

作者
Garofano F、Corsale AM、Biondo M、Romano A、Schmidt-Wolf I、Gullà AM、Siragusa S、Botta C
单位
Laboratory of Experimental Hematology and Immunogenomics, University Hospital of Palermo, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Hematology Unit, University of Palermo, Palermo, Italy.Italy
期刊
Frontiers in medicine2025
原文标识
PubMed 41608427 · DOI 10.3389/fmed.2025.1737919